Atara Biotherapeutics (NASDAQ:ATRA) Issues Earnings Results, Beats Estimates By $0.84 EPS

Atara Biotherapeutics (NASDAQ:ATRA) released its quarterly earnings data on Tuesday. The biotechnology company reported ($2.93) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.77) by $0.84, Zacks reports. The business had revenue of $40.19 million for the quarter, compared to analysts’ expectations of $23.00 million. During the same quarter in the prior year, the firm earned ($16.50) earnings per share.

Atara Biotherapeutics Trading Up 19.8 %

Shares of NASDAQ:ATRA traded up $2.31 on Wednesday, hitting $13.98. The company’s stock had a trading volume of 223,536 shares, compared to its average volume of 106,492. The stock’s 50-day moving average is $8.79 and its two-hundred day moving average is $10.27. Atara Biotherapeutics has a 12 month low of $6.48 and a 12 month high of $39.50.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on ATRA shares. HC Wainwright restated a “neutral” rating on shares of Atara Biotherapeutics in a research report on Wednesday, August 21st. The Goldman Sachs Group cut their price target on Atara Biotherapeutics from $12.50 to $11.00 and set a “sell” rating on the stock in a report on Wednesday, July 17th. Mizuho upgraded Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and lowered their price objective for the stock from $25.00 to $18.00 in a research note on Friday, August 16th. Finally, Canaccord Genuity Group raised their target price on Atara Biotherapeutics from $13.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $16.67.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.